Skip to content

What Is a Clinical Study Report? ICH E3 Structure and Writing Guide

Learn what a clinical study report is, ICH E3’s 16 sections & how AI medical writing tools accelerate CSR drafting for regulatory submissions.

A Clinical Study Report (CSR) is a comprehensive document that presents the methods, results, and conclusions of a clinical trial. It captures the full scientific and clinical record of how a study was conducted, what it found, and what those findings mean for the safety and efficacy of the investigational product.

For regulatory purposes, the CSR is the primary document submitted in Module 5, Section 5.3 of the Common Technical Document (CTD). Regulators at the FDA, EMA, and other health authorities use it to evaluate whether the clinical evidence from an individual trial supports the broader benefit-risk conclusions presented in a marketing application.

ICH E3, the International Council for Harmonisation guideline on the Structure and Content of Clinical Study Reports, establishes the internationally accepted framework for organizing CSR content. It is designed to ensure that the information regulators need to evaluate a trial's conduct and findings is presented consistently, regardless of the sponsor, the therapeutic area, or the market to which the application is directed.

What Are the 16 Sections of a Clinical Study Report Under ICH E3?

ICH E3 defines 16 sections that together form the standard CSR structure:

Section

Content

1. Title Page

Trial identification, sponsor, investigational product, protocol number, and report date

2. Synopsis

Structured summary of objectives, methods, and numerical results

3. Table of Contents

Maps all sections, figures, and appendices within the report

4. List of Abbreviations and Definition of Terms

Defines all abbreviations and specialized terminology used in the report

5. Ethics

Ethics committee approvals, informed consent procedures, and GCP compliance

6. Investigators and Study Administrative Structure

Names, qualifications, and roles of investigators and study personnel

7. Introduction

Rationale for the study and therapeutic context of the investigational product

8. Study Objectives

Primary and secondary objectives, as defined in the protocol

9. Investigational Plan

Study design, patient population, treatment regimens, statistical methods, and planned changes

10. Study Patients

Disposition, demographics, protocol deviations, and patients excluded from analysis

11. Efficacy Evaluation

Primary and secondary efficacy results, statistical analyses, and clinical significance

12. Safety Evaluation

Adverse events, deaths, laboratory findings, vital signs, and other safety data

13. Discussion and Overall Conclusions

Interpretation of results against study objectives and clinical implications

14. Tables, Figures and Graphs Referred To But Not Included in the Text

Supporting data displays not embedded in the narrative

15. Reference List

Literature, regulatory guidance, and prior studies cited in the report

16. Appendices

Protocol and amendments, statistical documentation, patient data listings, and case report forms

Two sections have particular weight in practice:

  • Section 2, Synopsis: The structured summary regulators typically read first. ICH E3 recommends limiting it to about three pages and including numerical findings.

  • Section 16, Appendices: The full evidentiary record underlying the report, organized into four sub-sections:

    • Appendix 16.1: Study information and documentation, including protocol amendments and statistical documentation

    • Appendix 16.2: Patient data listings

    • Appendix 16.3: Case report forms for deaths, serious adverse events, and adverse-event-related withdrawals

    • Appendix 16.4: Individual patient data listings required in US submissions

What Types of Clinical Study Reports Are There?

ICH E3 recognizes two CSR formats in clinical trials:

Full CSR

A full Clinical Study Report is the standard format for controlled clinical trials designed to establish efficacy and for any controlled safety study. It documents study design, methodology, efficacy findings, safety findings, and statistical analyses in full, with complete appendix documentation.

Abbreviated CSR

An abbreviated Clinical Study Report is the condensed format permitted for certain categories of trials, including:

  • Uncontrolled studies

  • Studies not designed to establish efficacy

  • Flawed or aborted studies

The FDA's guidance on abbreviated reports further specifies that they are appropriate for studies not intended to contribute to the evaluation of product effectiveness. In every case, safety reporting requirements remain unchanged regardless of format. The safety evaluation section must provide comprehensive safety information, and all safety appendix documentation remains required.

The acceptability of an abbreviated CSR depends on the regulatory authority's review policy. Sponsors should confirm format requirements before initiating the report.

How Do You Write a Clinical Study Report?

Clinical Study Report authoring follows a sequence that connects protocol-level planning to the final submission-ready document:

  • Review Source Documents: Begin with a thorough review of the protocol, all amendments, and the Statistical Analysis Plan (SAP). These documents define the objectives, methods, and analytical approach the CSR narrative must reflect accurately.

  • Prepare the CSR Framework: Organize the report structure according to ICH E3's 16-section format, confirming which sections are relevant to the study design and what supporting documentation will populate each appendix.

  • Incorporate Study Results: Integrate Tables, Figures, and Listings (TFLs) with the efficacy and safety narrative sections. The CSR is drafted from locked study data, which forms the factual basis of all efficacy and safety claims.

  • Complete the Synopsis and Appendices: Draft the Synopsis after the main sections are complete, as it summarizes findings that cannot be accurately captured before the full report is written. Confirm that Appendix 16 documentation is complete and consistent with the narrative record.

  • Conduct Quality Control: Check numerical accuracy, internal cross-references, and alignment between the protocol, SAP, TFLs, and CSR narrative before the document moves to review. Identify and explain any deviations from planned study methods.

What Should You Check Before Finalizing a CSR?

Two researchers in lab coats and safety glasses reviewing data on a laboratory monitor

To avoid inconsistencies, go through these pre-finalization checks:

  • Protocol and SAP Alignment: Verify that the methods described in the CSR narrative match the protocol and SAP exactly. 

  • TFL Consistency: The TFL supports the document narrative of a CSR. Confirm that every numerical finding cited in the efficacy and safety sections matches the corresponding table, figure, or listing precisely. 

  • Cross-References: Check all internal cross-references between sections to ensure they point to the correct content and that the Table of Contents reflects the final document structure.

  • Appendix 16 Completeness: Confirm that all required Appendix 16 components are present, including protocol amendments, statistical documentation, patient data listings (Appendix 16.2), and case report forms for serious adverse events, deaths, and adverse-event-related withdrawals (Appendix 16.3).

  • Deviations from Planned Methods: Any changes to study methods, endpoints, or analytical approaches must be explicitly addressed in the report, with the timing of those changes relative to unblinding documented. 

How Can AI Accelerate Clinical Study Report Writing?

CSR authoring is one of the most resource-intensive deliverables in clinical development. The document draws on data from multiple source files, requires alignment across TFLs and narrative sections, and must be completed under regulatory submission deadlines.

AuroraPrime, AlphaLife Sciences' AI platform for automated regulatory documentation and medical authoring, addresses the most time-consuming stages of CSR production:

  • Protocol and SAP Content Reuse: AuroraPrime ingests source documents and uses their content to automatically populate data-independent CSR sections. Through medical writing automation, it eliminates the copy-paste effort and reduces manual drafting time across sections that mirror protocol and SAP language.

  • TFL Synchronization: TFL data connects directly to generated CSR content. When source data changes, AuroraPrime detects the upstream change and automatically updates linked sections, without requiring writers to manually track and reconcile each affected passage.

  • Automated QC: Automated QC checks identify inconsistencies, omissions, and unsupported statements before human review begins.

  • Documented Results: AlphaLife Sciences reports that AuroraPrime can increase CSR development efficiency and improve document authoring speed across regulatory and medical writing workflows.

Reach out to AlphaLife Sciences and explore AuroraPrime's CSR automation capabilities today.

Frequently Asked Questions About Clinical Study Reports

Is ICH E3 a Mandatory Template for Every Clinical Study Report?

ICH E3 is not a mandatory template in the strict sense, but it represents the globally accepted standard for CSR structure. It provides guidance through relevant topics within the 16-section structure, while acknowledging that specific requirements may vary by region and that local authorities should be consulted.

Does Every Clinical Study Require a Full CSR?

ICH E3 permits abbreviated CSRs for uncontrolled studies, studies not designed to establish efficacy, and seriously flawed or aborted studies. A full CSR is required for controlled trials and any controlled safety study. Even when an abbreviated format is acceptable, a complete account of safety findings is always required, and the safety evaluation section must provide comprehensive safety information. Sponsors should confirm format requirements with the relevant authority before the CSR is initiated.

Can a Clinical Study Report Be Prepared Before Database Lock?

A CSR cannot be finalized before database lock. The locked database underpins statistical analysis, and the CSR narrative is drafted from locked data, which forms the factual basis for all efficacy and safety claims. Sections that do not depend on study results (the introduction, study objectives, and investigational plan) can be drafted in advance using the protocol and SAP, allowing teams to prepare the structural framework before final data are available. 

Where Can Medical Writers Find Official ICH E3 Guidance?

The current ICH E3 guideline is available on the FDA's guidance documents page and covers the full 16-section structure, synopsis requirements, appendix contents, and the conditions under which abbreviated CSRs are acceptable.

Close